Urology Times - BPH news, treatments, and more. - UrologyTimes
Urology Times

ADVERTISEMENT

BPH

Majority of nocturia patients have nocturnal polyuria

November 1, 2009

A study shows that most patients with nocturia have nocturnal polyuria, which is consistent with other studies showing that overproduction of urine at night is a major contributory factor to nocturia in about 80% of patients.

Majority of nocturia patients have nocturnal polyuria

November 1, 2009

Drs. Shlomo Raz and Ja-Hong Kim discuss recent advances in the treatment of stress incontinence.

Two-thirds of BPH/LUTS patients don't receive meds

September 1, 2009

BPH and lower urinary tract symptoms are very common, increase as a function of age, and are often managed through watchful waiting.

Study: Light-activated BPH therapy safe, painless

September 1, 2009

Light-activated drug therapy for BPH has been shown to be safe and painless in a phase I/II trial.

BPH-related symptoms improve with PDE-5 inhibitor

June 1, 2009

Findings from a multicenter, randomized, double-blind, placebo-controlled study are consistent with previously reported data showing that tadalafil (Cialis) improves lower urinary tract symptoms associated with BPH.

Two-drug therapy effective in lower urinary tract symptoms, obstruction

May 1, 2009

Anticholinergic drugs also are effective and safe in men who have lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO) secondary to BPH, a new study suggests.

New alpha-blocker highly selective for urinary tract

May 1, 2009

A new alpha-blocker for the treatment of BPH shows positive results with minimal cardiovascular side effects, according to a presentation made during the European Association of Urology annual congress

Injectable agents may expand options for BPH

May 1, 2009

While medical therapy remains the mainstay of treatment for most men with symptomatic BPH and surgery is required for severe, progressive disease, injectables may offer a number of theoretical advantages.

Targeted BPH treatment safe, effective at 1 year

May 1, 2009

Transperineal intraprostatic injection of a PSA-activated protoxin (PRX302) provides lasting symptomatic relief and improvement in quality of life for men with BPH, according to 1-year follow-up data from a phase I study.

Urology Times E-News

Brings you the latest news and information twice each month.

Click here to view the E-News archives.

Sign up now to receive Urology Times E-news free of charge!

Practice ToolsPractice Tools
Coding Counselor
Coding Counselor

Simple and accurate ICD-9 code search. Start Here

Formulary Counselor
Formulary Counselor

Find health plan drug coverage in your area. Start Here

Patient Education
Patient Education

Print customized patient education handouts. Start Here

Surgical Video Center
Surgical Video Center

On-demand surgery demos and presentations. Start Here

ADVERTISEMENT



Click here